You are here

peanut allergy

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Motley Fool

Aimmune Therapeutics

Flag link:

Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Fierce Biotech

Stanford University

Flag link:

Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches

Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches

BioSpace

Aimmune Therapeutics

real world data

Flag link:

DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy

DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy

Pharmaceutical Business Review

DBV Technologies

Flag link:

Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug

Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug

NPR

Aimmune Therapeutics

Flag link:

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Biopharma Dive

Flag link:

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

Stat

advisory panels

Aimmune Therapeutics

Flag link:

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Endpoints

Flag link:

DBV Technologies Resubmits BLA for Peanut Allergy Treatment

DBV Technologies Resubmits BLA for Peanut Allergy Treatment

BioSpace

DBV Technologies

Flag link:

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

Endpoints

Aimmune Therapeutics

DBV Technologies

Flag link:

Vedanta Biosciences enrolls first patient in VE416 phase 1b/2 food allergy clinical study

Vedanta Biosciences enrolls first patient in VE416 phase 1b/2 food allergy clinical study

Pharmaceutical Business Review

Vedanta Biosciences

clinical trials

Flag link:

FDA schedules Aimmune's peanut allergy drug for September expert review

FDA schedules Aimmune's peanut allergy drug for September expert review

Biopharma Dive

Aimmune Therapeutics

Flag link:

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Endpoints

Flag link:

4 Blockbuster Drug Launches to Watch in 2019

4 Blockbuster Drug Launches to Watch in 2019

Motley Fool

Alexion Pharmaceuticals

Aimmune Therapeutics

rheumatoid arthritis

Flag link:

Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

BioSpace

Aimmune Therapeutics

Flag link:

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

Xconomy

DBV Technologies

Flag link:

Aimmune says shutdown blocks peanut allergy drug review

Aimmune says shutdown blocks peanut allergy drug review

Fierce Biotech

Aimmune Therapeutics

government shutdown

Flag link:

DBV Technologies pulls peanut allergy treatment from FDA review

DBV Technologies pulls peanut allergy treatment from FDA review

Stat

DBV Technologies

Flag link:

Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts

Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts

Endpoints

Aimmune Therapeutics

Flag link:

Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies

Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies

Endpoints

Aimmune Therapeutics

Flag link:

Pages